https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2001-11-01 / Exp. Hematol. 2001 Nov;29(11):1247-55
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2001-11-01 / Exp. Hematol. 2001 Nov;29(11):1247-552001-11-01 00:00:002001-11-01 00:00:00Dendritic cells in cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2000-11-01 / Blood 2000 Nov;96(9):3102-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2000-11-01 / Blood 2000 Nov;96(9):3102-82000-11-01 00:00:002000-11-01 00:00:00Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1999-06-01 / Clin. Cancer Res. 1999 Jun;5(6):1331-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1999-06-01 / Clin. Cancer Res. 1999 Jun;5(6):1331-81999-06-01 00:00:002019-02-15 08:39:12A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1997-04-01 / J. Clin. Oncol. 1997 Apr;15(4):1354-66
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1997-04-01 / J. Clin. Oncol. 1997 Apr;15(4):1354-661997-04-01 00:00:002020-06-23 09:47:26Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer
